Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using theemail support widget if the problem persists.
Be the First to Know and Act on Market Moving News.
PROCEED is an adaptive Phase IIb trial with Lu AG09222, an investigational mAb intended to block signaling by pituitary adenylate cyclase-activating polypeptide (PACAP), a...
VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational...